Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare and orphan diseases, with an emphasis on neurological conditions. The company was formerly known as Acasti Pharma and changed its name after refocusing its pipeline.

Its lead product candidate, GTx-104, is an injectable intravenous formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a life-threatening type of bleeding in the brain caused by a ruptured aneurysm. Nimodipine is currently given orally in this setting, and the company's formulation is intended to allow consistent delivery in hospital intensive care units, including to patients who cannot swallow.

Grace Therapeutics relies on a drug delivery approach that improves the solubility of existing medicines, and it seeks regulatory approval through pathways that reference previously approved drugs. The company is headquartered in New Jersey.